8-K: BiomX Secures NYSE Compliance Extension Until 2027

BiomX Inc. has received approval from the NYSE American for a compliance plan to address stockholders' equity deficiencies, extending its listing deadline to September 25, 2027.

Summary

• BiomX Inc. received formal notification on June 10, 2026, that the NYSE American accepted its plan to regain compliance with continued listing standards.
• The company was previously non-compliant with Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide due to a stockholders' deficit of $1.302 million as of December 31, 2025.
• The exchange has granted a compliance period extending through September 25, 2027.
• During this period, the company's stock will continue to trade on the NYSE American with a .BC (below compliance) indicator.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral-to-negative development; while the extension provides breathing room, the underlying financial distress and the threat of delisting remain significant concerns for shareholders.

Positives

• The NYSE American has formally accepted the company's compliance plan, preventing immediate delisting.
• The company has been granted a significant runway until September 25, 2027, to rectify its stockholders' equity deficit.
• Trading of the company's common stock will continue uninterrupted on the exchange during the compliance period.

Negatives

• The company remains in a state of non-compliance with NYSE American listing standards regarding stockholders' equity.
• The stock will carry a .BC (below compliance) indicator, which may negatively impact investor perception and liquidity.
• The company reported a stockholders' deficit of $1.302 million as of December 31, 2025.
• The company has a history of losses from continuing operations and net losses over the past five fiscal years.

Risks

• Failure to regain compliance by September 25, 2027, will result in the initiation of delisting proceedings.
• The company may fail to make progress consistent with the accepted compliance plan, leading to potential early delisting.
• The company faces a going concern qualification in its financial statements, indicating significant doubt about its ability to continue operations.
• There is no assurance that the company will have sufficient working capital to execute its business plans and strategic opportunities.

Future Outlook

The company intends to execute the initiatives outlined in its compliance plan to restore stockholders' equity and maintain its listing on the NYSE American, though it provides no guarantees of success.

Management Comments

• The company is committed to taking the actions set forth in the plan and intends to use all reasonable efforts to regain compliance within the plan period.

Industry Context

StockSavvy.ai notes that BiomX is navigating a precarious financial position common among small-cap biotech and defense-tech firms that rely on continuous capital infusions. The reliance on a compliance plan extension is a standard regulatory mechanism, but it highlights the ongoing struggle to maintain balance sheet health in a high-burn environment.

Comparison to Industry Standards

• The company's stockholders' deficit is a significant red flag compared to healthy peers in the defense and technology sectors.
• The use of a compliance plan extension is a common, albeit high-risk, strategy for companies facing delisting on the NYSE American.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's listing status and potential dilution if capital is raised to fix the equity deficit.
• Creditors may view the going concern qualification and equity deficit as increased credit risk.

Next Steps

• Execute the initiatives outlined in the compliance plan.
• Undergo periodic reviews by NYSE Regulation.
• Work toward restoring stockholders' equity to meet the minimum requirements by September 25, 2027.

Key Dates

Recommendation

The combination of a stockholders' deficit, a going concern qualification, and the threat of delisting makes this a high-risk investment that does not meet the criteria for institutional or conservative retail portfolios.

Keywords

BiomX, NYSE American, delisting, stockholders equity, compliance plan, PHGE, financial distress